Phase 3 study finds fezolinetant reduces the frequency and severity of menopausal hot flashes

Fezolinetant significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, associated with menopause, according to a Phase 3 industry-sponsored study being presented Saturday at ENDO 2022, the Endocrine Society's annual meeting in Atlanta, Ga.

source https://medicalxpress.com/news/2022-06-phase-fezolinetant-frequency-severity-menopausal.html